AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02364479
Drug: 25mg etanercept
RxNorm normalized name: etanercept 25 MG/ML
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 25mg per week
Trial: NCT01926782
Drug: Alirocumab
RxNorm normalized name: Alirocumab
DrugBank: Alirocumab (DB09302)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solution for injection, subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
Trial: NCT04344678
Drug: Sildenafil Citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esitalopram 20 mg tablet plus Sildenafil Citrate 50 mg tablet once daily
Trial: NCT00271323
Drug: docetaxel and cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemo-radiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy.
Trial: NCT00453271
Drug: NB-002
RxNorm normalized name: Nb
DrugBank: Niobium (DB13031)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00453271
Drug: Vehicle control
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02296398
Drug: Romidepsin
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Received romidepsin per standard of care or through a clinical trial for more than one cycle
Trial: NCT04736433
Drug: Sacubitril/Valsartan
RxNorm normalized name: SACUBITRIL/VALSARTAN
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sacubitril/Valsartan dispensing claim is used as the reference
Trial: NCT01936532
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01936532
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03036046
Drug: F901318 with fluconazole low dose
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: adverse events
Trial: NCT01378286
Drug: ARTESUNATE + AMODIAQUINE
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:~Route of administration:
Trial: NCT01378286
Drug: Chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:tablet Route of administration: oral
Trial: NCT03036046
Drug: F901318 with fluconazole high dose
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: adverse events
Trial: NCT03036046
Drug: F901318 with posaconazole
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: adverse events
Trial: NCT04077905
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100mg/m² ivgtt on day 1
Trial: NCT04077905
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mg/kg ivgtt or PO days 1 to 3, 0.75 mg/kg ivgtt or PO days 4 to 7, 0.25 mg/kg ivgtt or PO days 8 to 10, 0. 1 mg/kg ivgtt or PO days 11 to 14,
Trial: NCT02933697
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will be instructed to take one tablet of 2.5 mg twice daily: one tablet in the morning and one in the evening at approximately the same time every day (with about 12 hours gap) irrespective of the time of dialysis.
Trial: NCT02933697
Drug: Phenprocoumon
RxNorm normalized name: phenprocoumon
DrugBank: Phenprocoumon (DB00946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects in phenprocoumon treatment group will receive phenprocoumon individually adjusted to an INR of 2.0-3.0 as recommended in the appropriate SmPC for AF patients.
Trial: NCT00353418
Drug: Peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180 µg subcutaneously weekly for 48 weeks
Trial: NCT00353418
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg orally daily for 48 weeks
Trial: NCT00353418
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg or 1200 mg (based on patient weight of \< 75 kg or ≥ 75 kg, respectively) orally daily for 48 weeks
Trial: NCT00754910
Drug: porfimer sodium
RxNorm normalized name: Porfimer Sodium
DrugBank: Porfimer sodium (DB00707)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03602079
Drug: A166
RxNorm normalized name: A166
DrugBank: A166 (DB17413)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.
Trial: NCT00743379
Drug: TH-302
RxNorm normalized name: TH-9402 free base
DrugBank: TH-9402 free base (DB17148)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TH-302 will be administered by IV infusion over 30 minutes on Days 1, 8 and 15 of a 28- day cycle for Arm A and on Days 1 and 8 of a 21 day cycle for Arms B and C.
Trial: NCT00380328
Drug: neratinib
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: HKI-272
Trial: NCT00689572
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
Trial: NCT04266340
Drug: dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2.5µg/kg intranasal dexmedetomidine group
Trial: NCT04266340
Drug: midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.5mg/kg oral midazolam
Trial: NCT04266340
Drug: midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.05mg/kg intravenous injection midazolam
Trial: NCT04266340
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: no premedication
Trial: NCT02916940
Drug: Diprophos
RxNorm normalized name: Alclometasone Dipropionate
DrugBank: Alclometasone (DB00240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single subcutaneous injection of Diprophos, in the acute phase.
Trial: NCT04031703
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel chemotherapy (injection)
Trial: NCT04031703
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin chemotherapy (injection)
Trial: NCT04031703
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epirubicin chemotherapy (injection)
Trial: NCT04031703
Drug: 5-fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil chemotherapy (injection)
Trial: NCT04031703
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel chemotherapy (injection)
Trial: NCT03624322
Drug: Zydis
RxNorm normalized name: ZyPREXA Zydis
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg orally disintegrating wafer
Trial: NCT03828929
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV vitamin C, 1500mg in 50ml of normal saline every six hours, infused over one hour and IV Thiamine 200mg in 50ml of 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
Trial: NCT00261872
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01899170
Drug: 11C-Carfentanil
RxNorm normalized name: 11C-CARFENTANIL
DrugBank: Carfentanil, C-11 (DB15360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET-radioligand for functional brain imaging to assess opioid binding. The compound is a potent synthetic opioid.
Trial: NCT00003580
Drug: amifostine trihydrate
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003580
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01286246
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capsules of 200mg micronised progesterone suspended in sunflower oil. One capsule inserted vaginally per day from time of randomisation to gestational age 35(+6)weeks or delivery (if sooner).
Trial: NCT03239743
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Child will receive Midazolam to help with pre-operative anxiety prior to surgery
Trial: NCT03379389
Drug: Methenamine + Methylthioninium
RxNorm normalized name: Methenamine
DrugBank: Methenamine (DB06799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methenamine + Methylthioninium
Trial: NCT02809833
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab must be selected by the treating physician in advance of the study and will be not provided by the Sponsor. The dose/regimen are at the discretion of the prescriber. However, tocilizumab in the SmPC is specified as 8 milligrams per kilogram (mg/kg) via intravenous (IV) infusion at 4-week intervals.
Trial: NCT01948843
Drug: ADI-PEG 20
RxNorm normalized name: ADI-PEG 20
DrugBank: Pegargiminase (DB06592)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02686593
Drug: Clofarabine, AraC, mitoxantrone (CLAM)
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The combination of clofarabine, cytarabine (Ara-C) and mitoxantrone will be used in patients with AML in first relapse or after failure of first salvage
Trial: NCT03115151
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine (0.0625%) will be combined with fentanyl for postoperative epidural analgesia via a lumbar epidural catheter
Trial: NCT03115151
Drug: Hydromorphone
RxNorm normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydromorphone will be given continuous infusion for intravenous patient controlled analgesia (syringe 25 mg/50 mL).
Trial: NCT03379389
Drug: Methenamine + Methylthioninium + Acriflavine + Atropa belladona
RxNorm normalized name: Atropa belladona
DrugBank: Methenamine (DB06799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methenamine + Methylthioninium + Acriflavine + Atropa belladona
Trial: NCT01622881
Drug: Nefopam
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam 160mg (16 mL) mixed to normal saline 184 mL : the infusion of 4mL/hr for post-operative 48 hours
Trial: NCT01728064
Drug: EPI-743 400 mg
RxNorm normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01728064
Drug: EPI-743 200 mg
RxNorm normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03823612
Drug: Clinpro Tooth Creme
RxNorm normalized name: sodium fluoride 0.950 mg in 1 g ORAL PASTE, DENTIFRICE [Clinpro Tooth Creme]
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The participant will be instructed to Place a pea-sized amount of Clinpro Tooth Crème on a soft bristled toothbrush and brush teeth for at least two minutes then after brushing the patient will rinse out his mouth with water and spit out. It will be used twice daily at first in the morning and before sleep.
Trial: NCT00876135
Drug: Ventolin
RxNorm normalized name: Ventolin
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventolin or Placebo will be given before the 4 field tests (2 with ventolin in prevention and 2 with placebo in prevention) and 2 eucapnic voluntary hyperpnoea tests (one preceded by Ventolin and one preceded by Placebo).
Trial: NCT01306227
Drug: L-Thyroxine
RxNorm normalized name: L-Thyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment with L-Thyroxine:7,5 µg/kg/day. Oral treatment (one drop =5µg) in the morning, once a day.
Trial: NCT01306227
Drug: water
RxNorm normalized name: Water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral treatment with water. Equal number of drop of water as compared with the treatment arm (according to the body weight of the newborn) in the morning, once a day.
Trial: NCT03680495
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Methylprednisolone is a steroid (corticosteroid) similar to a product produced in the adrenal glands. It is used to help relieve inflammation (swelling, heat, redness, and pain) and is used to treat certain medical issues including COPD.
Trial: NCT05749380
Drug: AmBisome
RxNorm normalized name: AmBisome
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference, dose of 3 mg/kg.
Trial: NCT05749380
Drug: DKF-5122
RxNorm normalized name: DKFZ-PSMA-11 Ga-68
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test, dose of 3 mg/kg
Trial: NCT04509466
Drug: Part 1: Liposomal mitoxantrone hydrochloride and Pegaspargase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Liposomal mitoxantrone hydrochloride (12mg/m2, 16mg/m2, 20mg/m2, 24mg/m2) is administered by an intravenous infusion (IV) on day 1 of each 21-day cycle.~Drug: Pegaspargase (2000IU/m2) is administered by an intramuscular injection (IM) on day 1 of each 21-day cycle.
Trial: NCT04509466
Drug: Part 2 (treatment-naïve patients): Liposomal mitoxantrone hydrochloride and Pegaspargase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Liposomal mitoxantrone hydrochloride (RP2D defined in Part 1) is administered by an intravenous infusion (IV) on day 1 of each 21-day cycle.~Drug: Pegaspargase (2000IU/m2) is administered by an intramuscular injection (IM) on day 1 of each 21-day cycle.
Trial: NCT02528279
Drug: Coartem
RxNorm normalized name: Coartem
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive the study drug combination artemether-lumefantrine (Coartem®) orally as a 6 dose regimen for three consecutive days. Tablets are available as a fixed dose combination of 20mg artemether plus 120mg lumefantrine. The dosing will be based on the body weight and follow the manufacturer's recommendations:~Body weight 5-14kg: 1 tablet; Body weight 15-24kg: 2 tablets; Body weight 25-34kg: 3 tablets; Body weight \> 34kg: 4 tablets; The respective amount of tablets is to be taken at hours 0, 8, 24, 36, 48 and 60 with fatty food.
Trial: NCT04509466
Drug: Part 2 (relapsed or refractory patients): Liposomal mitoxantrone hydrochloride and Pegaspargase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Liposomal mitoxantrone hydrochloride (RP2D defined in Part 1) is administered by an intravenous infusion (IV) on day 1 of each 21-day cycle.~Drug: Pegaspargase (2000IU/m2) is administered by an intramuscular injection (IM) on day 1 of each 21-day cycle.
Trial: NCT01402297
Drug: Apocynin and placebo nebulization
DrugBank: Apocynin (DB12618)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 ml of apocynin of total dose 3 mg (0.5 mg/ml dissolved in sterile 0.9% NaCl as the study drug) and 0,9% NaCl as placebo, has been nebulized for 15-20 min through the mouthpiece with using of a nose clip. A nebulizer Pulmo Aide AP-50 (DeVilbiss; Richmond, VA) was used (mass median aerosol diameter 3.1 mm, output 0.3 ml/min.)
Trial: NCT02100917
Drug: trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00027664
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03893487
Drug: Fimepinostat
RxNorm normalized name: Fimepinostat
DrugBank: Fimepinostat (DB11891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimepinostat capsules
Trial: NCT03090880
Drug: Tinzaparin Sodium
RxNorm normalized name: Tinzaparin Sodium
DrugBank: Tinzaparin (DB06822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous tinzaparin 4,500 IU once daily for six months.
Trial: NCT01405248
Drug: Butylphthalide
RxNorm normalized name: BUTYLPHTHALIDE
DrugBank: Butylphthalide (DB12749)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/time per os three times a day. 180days
Trial: NCT00293579
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg/m2 IV every 3 weeks for 6 cycles
Trial: NCT00066898
Drug: AGI-1067
RxNorm normalized name: AGI-134
DrugBank: AGI-134 (DB19005)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02957305
Drug: Misoprostol 400mcg Tab
RxNorm normalized name: Misoprostol Tablets
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400µg of misoprostol (2 tablets)
Trial: NCT02957305
Drug: Misoprostol 200mcg Tab
RxNorm normalized name: MISOPROSTOL 200MCG TAB
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200µg of misoprostol (1 tablet)
Trial: NCT02282579
Drug: Pazopanib
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Non interventional study
Trial: NCT05599997
Drug: Pecavaptan (BAY1753011)
RxNorm normalized name: Pecavaptan
DrugBank: Pecavaptan (DB16279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg, immediate release tablet, single dose, oral
Trial: NCT05599997
Drug: Pecavaptan (BAY1753011)
RxNorm normalized name: Pecavaptan
DrugBank: Pecavaptan (DB16279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg, immediate release tablet, single dose, oral
Trial: NCT00352105
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg/m2/d IV continuous infusion x4 days
Trial: NCT00352105
Drug: Iressa
RxNorm normalized name: Iressa
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250mg/PO qd x 2 years
Trial: NCT00796315
Drug: Doxylamine Succinate USP
RxNorm normalized name: Doxylamine Succinate
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One dose of liquid, dosing range 3.125mg/7.5mL - 12.5mg/30mL
Trial: NCT01487915
Drug: GCb
RxNorm normalized name: GA-GCB
DrugBank: Velaglucerase alfa (DB06720)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemcitabine 1000 mg/㎡ D1, D8 plus Carboplatin AUC=4.5 D1 every 3 weeks
Trial: NCT01487915
Drug: GemOx
RxNorm normalized name: Hemox A
DrugBank: Aluminum chloride (DB11081)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/㎡ D1 plus Oxaliplatin 100 mg/㎡ D1 every 2 weeks
Trial: NCT01637376
Drug: Temoporfin
RxNorm normalized name: Temoporfin
DrugBank: Temoporfin (DB11630)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: A single dose of 0.04 mg per kilogram of body weight of Temoporfin will be administered by slow intravenous injection into a deep vein (such as the antecubital vein) in not less than 6 minutes and will not be flushed with sodium chloride or any other aqueous solution.
Trial: NCT01101620
Drug: Levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01007084
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg
Trial: NCT01007084
Drug: Propranolol ER
RxNorm normalized name: Propranolol Hydrochloride 80 MG Oral Capsule, Extended Release [PROPRANOLOL ER]
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 120 mg twice per day
Trial: NCT01007084
Drug: Sugar pills
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar pill
Trial: NCT01278498
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: first week:5mg 2nd week\~12 week:10mg
Trial: NCT01278498
Drug: sugar pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: first week:5mg 2nd week\~12 weeks:10mg
Trial: NCT03667703
Drug: Famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to either receive a placebo or famotidine (study drug).